0001564590-19-037552.txt : 20191023 0001564590-19-037552.hdr.sgml : 20191023 20191023161523 ACCESSION NUMBER: 0001564590-19-037552 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20191023 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191023 DATE AS OF CHANGE: 20191023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEXTGEN HEALTHCARE, INC. CENTRAL INDEX KEY: 0000708818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 952888568 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12537 FILM NUMBER: 191163918 BUSINESS ADDRESS: STREET 1: 18111 VON KARMAN AVENUE STREET 2: SUITE 800 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-255-2600 MAIL ADDRESS: STREET 1: 18111 VON KARMAN AVENUE STREET 2: SUITE 800 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: QUALITY SYSTEMS, INC DATE OF NAME CHANGE: 20180823 FORMER COMPANY: FORMER CONFORMED NAME: NEXTGEN HEALTHCARE, INC DATE OF NAME CHANGE: 20180823 FORMER COMPANY: FORMER CONFORMED NAME: QUALITY SYSTEMS, INC DATE OF NAME CHANGE: 20100804 8-K 1 nxgn-8k_20191023.htm 8-K nxgn-8k_20191023.htm
false 0000708818 0000708818 2019-10-23 2019-10-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report

(Date of earliest event reported):

October 23, 2019

 

NEXTGEN HEALTHCARE, INC.

(Exact name of Registrant as Specified in Its Charter)

 

California

001-12537

95-2888568

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

 

18111 Von Karman Avenue, Suite 800

Irvine, California

 

92612

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 255-2600

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock (Par Value $0.01)

 

NXGN

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On October 23, 2019, NextGen Healthcare, Inc. (the “Company”) issued a press release announcing its financial performance for the period ended September 30, 2019. A copy of the press release is attached to this Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

The information in this Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Description

99.1

104

 

Press Release dated October 23, 2019.

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 23, 2019

NEXTGEN HEALTHCARE, INC.

 

 

 

 

By:

/s/ James R. Arnold, Jr.

 

 

James R. Arnold, Jr.

 

 

Chief Financial Officer

 

 

 

 EX-99.1 2 nxgn-ex991_6.htm EX-99.1 nxgn-ex991_6.htm

Exhibit 99.1

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

October 23, 2019

 

NextGen Healthcare, Inc. Reports Fiscal 2020 Second Quarter

IRVINE, Calif. – (BUSINESS WIRE) – NextGen Healthcare, Inc. (NASDAQ: NXGN), a leading provider of ambulatory-focused healthcare technology solutions, announced today its fiscal 2020 second quarter ended September 30, 2019 operating results.

 

Fiscal 2020 Second Quarter Highlights

On a GAAP basis, revenue for the fiscal 2020 second quarter was $134.3 million compared to $130.3 million a year ago.

 

On a GAAP basis, net income for the fiscal 2020 second quarter was $6.1 million compared with net income of $13.1 million in the fiscal 2019 second quarter.

 

On a GAAP basis, fully diluted net income per share was $0.09 in the fiscal 2020 second quarter compared to net income per share of $0.20 per share for the same period a year ago. On a non-GAAP basis, fully diluted earnings per share for the fiscal 2020 second quarter remained at $0.24 compared to the second quarter a year ago.

 

Cash flow from operations was $23.8 million in the fiscal 2020 second quarter compared to $11.9 million for the same period a year ago.  Free cash flow was $17.1 million compared to $5.5 million in the same period a year ago.  

 

“I’m pleased to report a solid second quarter in which we delivered revenue growth and positive free cash flow, as well as strong bookings bolstered by cross-selling, RCM traction, multiple “all-in” deals, and competitive displacements. Immediately after quarter end, we completed the acquisition of Topaz Information Solutions, which expands our capabilities to better serve behavioral health providers and enables our planned growth in this important market. Halfway through our fiscal year, we are confident that our current position will enable us to deliver on our full year outlook,” said Rusty Frantz, president and chief executive officer of NextGen Healthcare.

 

Fiscal 2020 Financial Outlook

The Company is reiterating their outlook for fiscal 2020 and expects:

 

•

Revenue of between $536 million and $550 million

 

•

Non-GAAP EPS of between $0.82 and $0.90

 

Conference Call Information

NextGen Healthcare will host a conference call to discuss its fiscal 2020 second quarter operating results on Wednesday, October 23, 2019 at 5:00 PM ET (2:00 PM PT). Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-750-8947 or 720-405-1352 for international callers, and

referencing participant code 7179172 approximately 15 minutes prior to the call. A recording of the live webcast will be available on investor.nextgen.com after the call. It will be archived for 90 days until January 22, 2020.

About NextGen Healthcare, Inc

We empower the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn and Instagram.

 

Media Contact:
NextGen Healthcare
Cynthia Ragland
(949) 255-2600 x 75416
cragland@nextgen.com

or

Investor Contact:

Westwicke Partners

Bob East or Asher Dewhurst

Westwicke Partners

443-213-0500

 

 

SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to, statements regarding future events, developments in the healthcare sector and regulatory framework, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements. Factors that could cause the anticipated results to differ from those described in the forward-looking statements and additional risks and uncertainties are set forth in Part I, Item A of our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, including but not limited to: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; seasonal patterns of sales and customer buying behavior; impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; uncertainties related to the future impact of U.S. tax reform; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; changes of accounting estimates and assumptions used to prepare the prior periods' financial statements; disruptions caused by acquisitions of companies, products, or technologies; and general economic conditions. A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in

quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

USE OF NON-GAAP FINANCIAL MEASURES

This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S. GAAP. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. The Company calculates free cash flow by as total net cash provided by operating activities, net of cash used for the additions of capitalized software costs and equipment and improvements. The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, restructuring costs, net securities litigation defense costs and settlement, share-based compensation, impairment of assets, and other non-run-rate expenses from GAAP income before provision for income taxes.

 

The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each quarter of fiscal year 2019 was 22.0% and is expected to remain at 22.0% for each quarter of fiscal year 2020. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

 

The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, restructuring costs, net securities litigation defense costs, impairment of assets, and other non-run-rate expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.

 


NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

Three Months Ended September 30,

 

 

Six Months Ended September 30,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recurring

$

120,589

 

 

$

116,317

 

 

$

240,036

 

 

$

236,324

 

Software, hardware, and other non-recurring

 

13,667

 

 

 

14,004

 

 

 

26,081

 

 

 

27,197

 

Total revenues

 

134,256

 

 

 

130,321

 

 

 

266,117

 

 

 

263,521

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recurring

 

50,328

 

 

 

47,172

 

 

 

100,868

 

 

 

95,325

 

Software, hardware, and other non-recurring

 

6,563

 

 

 

7,022

 

 

 

12,841

 

 

 

14,176

 

Amortization of capitalized software costs and acquired intangible assets

 

8,843

 

 

 

6,924

 

 

 

17,256

 

 

 

13,468

 

Total cost of revenue

 

65,734

 

 

 

61,118

 

 

 

130,965

 

 

 

122,969

 

Gross profit

 

68,522

 

 

 

69,203

 

 

 

135,152

 

 

 

140,552

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

39,046

 

 

 

34,229

 

 

 

79,174

 

 

 

78,865

 

Research and development costs, net

 

19,789

 

 

 

18,371

 

 

 

41,840

 

 

 

40,499

 

Amortization of acquired intangible assets

 

865

 

 

 

1,121

 

 

 

1,730

 

 

 

2,289

 

Impairment of assets

 

1,916

 

 

 

—

 

 

 

2,405

 

 

 

—

 

Restructuring costs

 

175

 

 

 

—

 

 

 

1,882

 

 

 

—

 

Total operating expenses

 

61,791

 

 

 

53,721

 

 

 

127,031

 

 

 

121,653

 

Income from operations

 

6,731

 

 

 

15,482

 

 

 

8,121

 

 

 

18,899

 

Interest income

 

36

 

 

 

40

 

 

 

115

 

 

 

69

 

Interest expense

 

(387

)

 

 

(769

)

 

 

(859

)

 

 

(1,499

)

Other income, net

 

210

 

 

 

237

 

 

 

77

 

 

 

611

 

Income before provision for income taxes

 

6,590

 

 

 

14,990

 

 

 

7,454

 

 

 

18,080

 

Provision for income taxes

 

509

 

 

 

1,896

 

 

 

129

 

 

 

2,338

 

Net income

$

6,081

 

 

$

13,094

 

 

$

7,325

 

 

$

15,742

 

Net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.09

 

 

$

0.20

 

 

$

0.11

 

 

$

0.25

 

Diluted

$

0.09

 

 

$

0.20

 

 

$

0.11

 

 

$

0.24

 

Weighted-average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

65,401

 

 

 

64,265

 

 

 

65,209

 

 

 

64,143

 

Diluted

 

65,560

 

 

 

64,857

 

 

 

65,445

 

 

 

64,362

 


NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

 

 

 

September 30, 2019

 

 

March 31, 2019

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

42,930

 

 

$

33,079

 

Restricted cash and cash equivalents

 

 

7,501

 

 

 

1,443

 

Accounts receivable, net

 

 

83,708

 

 

 

87,459

 

Contract assets

 

 

11,973

 

 

 

13,242

 

Inventory

 

 

58

 

 

 

120

 

Income taxes receivable

 

 

3,272

 

 

 

3,682

 

Prepaid expenses and other current assets

 

 

20,612

 

 

 

20,826

 

Total current assets

 

 

170,054

 

 

 

159,851

 

Equipment and improvements, net

 

 

22,049

 

 

 

21,404

 

Capitalized software costs, net

 

 

39,076

 

 

 

37,855

 

Operating lease assets

 

 

38,230

 

 

 

—

 

Deferred income taxes, net

 

 

6,166

 

 

 

6,194

 

Contract assets, net of current

 

 

3,175

 

 

 

3,747

 

Intangibles, net

 

 

42,290

 

 

 

52,595

 

Goodwill

 

 

218,771

 

 

 

218,771

 

Other assets

 

 

33,017

 

 

 

32,478

 

Total assets

 

$

572,828

 

 

$

532,895

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

4,837

 

 

$

5,432

 

Contract liabilities

 

 

54,101

 

 

 

56,009

 

Accrued compensation and related benefits

 

 

21,825

 

 

 

25,663

 

Income taxes payable

 

 

—

 

 

 

64

 

Operating lease liabilities

 

 

9,947

 

 

 

—

 

Other current liabilities

 

 

41,545

 

 

 

41,064

 

Total current liabilities

 

 

132,255

 

 

 

128,232

 

Deferred compensation

 

 

5,933

 

 

 

5,905

 

Line of credit

 

 

—

 

 

 

11,000

 

Operating lease liabilities, net of current

 

 

41,622

 

 

 

—

 

Other noncurrent liabilities

 

 

1,890

 

 

 

11,812

 

Total liabilities

 

 

181,700

 

 

 

156,949

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

 

 

$0.01 par value; authorized 100,000 shares; issued and outstanding 65,436 and 64,838 shares at September 30, 2019 and March 31, 2019, respectively

 

 

654

 

 

 

648

 

Additional paid-in capital

 

 

272,848

 

 

 

264,908

 

Accumulated other comprehensive loss

 

 

(1,320

)

 

 

(1,231

)

Retained earnings

 

 

118,946

 

 

 

111,621

 

Total shareholders' equity

 

 

391,128

 

 

 

375,946

 

Total liabilities and shareholders' equity

 

$

572,828

 

 

$

532,895

 


NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

 

 

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE

 

 

Three Months Ended September 30,

 

 

Six Months Ended September 30,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Income before provision for income taxes - GAAP

$

6,590

 

 

$

14,990

 

 

$

7,454

 

 

$

18,080

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition costs, net

 

739

 

 

 

315

 

 

 

739

 

 

 

1,949

 

Amortization of acquired intangible assets

 

5,152

 

 

 

5,409

 

 

 

10,305

 

 

 

10,865

 

Amortization of deferred debt issuance costs

 

178

 

 

 

178

 

 

 

355

 

 

 

355

 

Impairment of assets

 

1,916

 

 

 

—

 

 

 

2,405

 

 

 

—

 

Restructuring costs

 

175

 

 

 

—

 

 

 

1,882

 

 

 

—

 

Securities litigation defense costs and settlement, net of insurance

 

339

 

 

 

(5,715

)

 

 

376

 

 

 

(5,436

)

Share-based compensation

 

4,316

 

 

 

4,135

 

 

 

9,207

 

 

 

7,251

 

Other non-run-rate expenses*

 

815

 

 

 

691

 

 

 

905

 

 

 

2,639

 

Total adjustments to GAAP income before provision for income taxes:

 

13,630

 

 

 

5,013

 

 

 

26,174

 

 

 

17,623

 

Income before provision for income taxes - Non-GAAP

 

20,220

 

 

 

20,003

 

 

 

33,628

 

 

 

35,703

 

Provision for income taxes

 

4,448

 

 

 

4,401

 

 

 

7,398

 

 

 

7,855

 

Net income - Non-GAAP

$

15,772

 

 

$

15,602

 

 

$

26,230

 

 

$

27,848

 

Diluted net income per share - Non-GAAP

$

0.24

 

 

$

0.24

 

 

$

0.40

 

 

$

0.43

 

Weighted-average shares outstanding (diluted):

 

65,560

 

 

 

64,857

 

 

 

65,445

 

 

 

64,362

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Other non-run-rate expenses for the three and six months ended September 30, 2019 consist primarily of excess lease-related expense for vacated facilities and other costs, including retention bonuses, related to the restructuring plan. Other non-run-rate expenses for the three and six months ended September 30, 2018 consist primarily of severance and other employee-related costs.

 

 

 

 

 GRAPHIC 3 gpl3qaml4lso000001.jpg GRAPHIC begin 644 gpl3qaml4lso000001.jpg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�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nxgn-20191023.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 nxgn-20191023_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 nxgn-20191023_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nxgn-8k_20191023.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "nxgn-8k_20191023.htm" ] }, "labelLink": { "local": [ "nxgn-20191023_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nxgn-20191023_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nxgn-20191023.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nxgn", "nsuri": "http://www.nextgen.com/20191023", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "nxgn-8k_20191023.htm", "contextRef": "C_0000708818_20191023_20191023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "nxgn-8k_20191023.htm", "contextRef": "C_0000708818_20191023_20191023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 9 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document And Entity Information
Oct. 23, 2019
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 23, 2019
Entity Registrant Name NEXTGEN HEALTHCARE, INC.
Entity Central Index Key 0000708818
Entity Emerging Growth Company false
Entity File Number 001-12537
Entity Incorporation, State or Country Code CA
Entity Tax Identification Number 95-2888568
Entity Address, Address Line One 18111 Von Karman Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92612
City Area Code 949
Local Phone Number 255-2600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock (Par Value $0.01)
Trading Symbol NXGN
Security Exchange Name NASDAQ
XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 11 0001564590-19-037552-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-037552-xbrl.zip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end XML 12 nxgn-8k_20191023_htm.xml IDEA: XBRL DOCUMENT 0000708818 2019-10-23 2019-10-23 false 0000708818 8-K 2019-10-23 NEXTGEN HEALTHCARE, INC. CA 001-12537 95-2888568 18111 Von Karman Avenue Suite 800 Irvine CA 92612 949 255-2600 false false false false Common Stock (Par Value $0.01) NXGN NASDAQ false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.nextgen.com/20191023/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports nxgn-8k_20191023.htm nxgn-20191023.xsd nxgn-20191023_lab.xml nxgn-20191023_pre.xml nxgn-ex991_6.htm http://xbrl.sec.gov/dei/2019-01-31 true false